Prabhudas Lilladher's research report on PI Industries
In CY11, PI Industries (PI) launched pyroxasulfone (pyroxa) – an event that sparked the interests of investors and offered them a journey of 28% CAGR in market cap based on 19%/23%/26% CAGR in sales/EBITDA/PAT until FY25. However, 7% decline in Kumiai’s (innovator) guidance on sales of pyroxa for Nov’24-Oct’25, is likely to affect PI’s CSM segment with revenue clocking 6% CAGR in FY25–28E compared with 21% CAGR in the past 5 years. The pharma business, still in ramp-up, is projected to grow ~70% in FY26 and break even by FY28 at ~Rs5bn revenue. The domestic business is expected to deliver ~6% CAGR, led by biologicals, while core formulations remain subdued. We estimate consolidated revenue/EBITDA/PAT CAGR at ~7%/8%/7% over FY25–28E, supported by new CSM launches, biologicals and pharma scale-up.
Outlook
At 28x FY27E EPS, the stock is trading slightly above its sector average. While R&D spending (3% of sales) remains strong, we await the next spark that could once again spur investors’ interests. We initiate coverage on PI with ‘HOLD’ recommendation and TP of Rs3,618 (28x Sep’27 EPS).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.